Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/27/2015)... 27, 2015  Two mass spectrometry technologies ... as their effectiveness is established, according to ... Information says that while mass spectrometry (mass ... tool in proteomic biomarker discovery and validation, ... traditional techniques has struggled to elucidate molecular ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... of 5,250,000 shares of its common stock at a ... net proceeds to Tandem from this offering are expected ... commissions and other estimated offering expenses payable by Tandem. ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... Jan. 17, 2012 To address the growing need ... with the automation of routine clinical laboratory assays, ... Tecan Group (SIX Swiss Exchange: TECN) today entered into ... handling platform with Waters® ACQUITY® TQD liquid ...
... RIVER EDGE, N.J., Jan. 17, 2012  Nephros, Inc. (OTC ... developing and marketing filtration products for therapeutic applications, infection ... 16, 2012, Nephros received a payment of euro 750,000 ... Under the terms of the license agreement ...
Cached Medicine Technology:Waters and Tecan Sign Agreement for Clinical Assay Platform 2Waters and Tecan Sign Agreement for Clinical Assay Platform 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 2Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 4
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... Fredericton, NB (PRWEB) February 28, 2015 ... call center software suite for Asterisk, are pleased to ... the highly successful 5.7 and 5.8 versions of Q-Suite, ... as well as a number of new features to ... be Q2 2015. , Q-Suite 5.9 will add features ...
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... 2015 Pioneer Millworks reclaimed USA wood ... & Construction Materials Show, an annual, premier sustainable building ... suppliers and top manufacturers of the latest building products, ... sourced and manufactured by Pioneer Millworks from their ... Japan at restaurants, hotels, retailers, and corporate offices. ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... The National Institutes of Health announced today a second ... including funds for 19 research consortia. The Rare Diseases ... (DMCC) will be awarded a total of just over ... conducted with the new funding will explore the natural ...
... cancer-related deaths in the United States, leading to over ... with early screening using a procedure called a colonoscopy. ... and the University of Massachusetts at Amherst (UMass) have ... efficiently, ultimately lowering costs and leading to shorter waiting ...
... The dangers of secondhand smoke have led some organizations ... and other public venues. The effectiveness of such ... breathing environmental tobacco smoke has been a matter of ... Sense of the Evidence, a new report from the ...
... The American College of Preventive Medicine (ACPM) supports the ... that primary care providers should screen all adults for ... should have systems in place to ensure the accurate ... and best opportunities to identify depression are in the ...
... ... medical tourism in the press - the savings that can be made and the quality of ... consider surgery overseas. , ... 6, 2009 -- Medical tourism has been around since the Romans. In recent years however, growing ...
... ... Medicare and Medicaid Services , ... Houston, TX (PRWEB) October 6, 2009 -- KelseyCare Advantage , a ... Harris, Fort Bend, Montgomery, and Galveston on the Mainland, recently reported its Healthcare Effectiveness ...
Cached Medicine News:Health News:NIH announces expansion of Rare Diseases Clinical Research Network 2Health News:NIH announces expansion of Rare Diseases Clinical Research Network 3Health News:NIH announces expansion of Rare Diseases Clinical Research Network 4Health News:NIH announces expansion of Rare Diseases Clinical Research Network 5Health News:NIH announces expansion of Rare Diseases Clinical Research Network 6Health News:NIH announces expansion of Rare Diseases Clinical Research Network 7Health News:NIH announces expansion of Rare Diseases Clinical Research Network 8Health News:Study shows how to lower costs, waiting times for colonoscopies 2Health News:85% of People Would Consider Medical Tourism 2Health News:85% of People Would Consider Medical Tourism 3Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Sabre 180 is a powerful niche generator....
Medicine Products: